Literature DB >> 21959988

Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma.

Guner Hayri Ozsan1, Ivana N Micallef, Angela Dispenzieri, Shaji Kumar, Martha Q Lacy, David Dingli, Suzanne R Hayman, Francis K Buadi, Robert C Wolf, Dennis A Gastineau, William J Hogan, Morie A Gertz.   

Abstract

Autologous stem cell transplantation is an important part of therapy in patients with multiple myeloma. Some patients fail to collect the desired number of stem cells while others require multiple apheresis to reach the desired apheresis target. The aim of this study was to determine the predictive factors and if the hematopoietic kinetics of recovery were predictive for outcome of stem cell mobilization in cyclophosphamide + growth factor (CY-GF) mobilized patients. Three hundred and ninety six consecutive CY-GF mobilization attempts between January 2000 and December 2009 at Mayo Clinic, Rochester, MN were analyzed. Patients were divided into three groups: optimal (>5 × 10(6) CD34/kg), suboptimal (2-5 × 10(6) CD34/kg) and poor (<2 × 10(6) /kg CD34+ cells) mobilization groups. About 86% of patients had optimal stem cell collection, whereas 8% had suboptimal collection and 6% had poor (or failed) collections. Age, Hb, WBC, and platelet levels had an impact on mobilization results. Time to peripheral blood (PB) CD34+cells >10/μL predicted for efficiency of collection and the interval between recovery of WBC>1 post-CY to PB CD34+ cells>10 was shorter in the optimal collection groups. These findings suggest that for patients with a PB CD34+ cell count below 10/μL on Day 13 following CY or 1 day after the WBC>1 × 10(9) /L, addition of plerixafor may be helpful to salvage the mobilization attempt.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959988     DOI: 10.1002/ajh.22179

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.

Authors:  S Afifi; N G Adel; S Devlin; E Duck; J Vanak; H Landau; D J Chung; N Lendvai; A Lesokhin; N Korde; L Reich; O Landgren; S Giralt; H Hassoun
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 2.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

3.  Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.

Authors:  Giuseppe Milone; Giovanni Tripepi; Massimo Martino; Flavia Ancora; Benedetta Bartolozzi; Andrea Spadaro; Chiara Nozzoli; Alessia La Fauci; Irene Amico; Salvatore Leotta; Massimo Poidomani; Giuseppe Irrera; Pasquale Iacopino; Riccardo Saccardi; Stefano Guidi; Alberto Bosi
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

4.  Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.

Authors:  Pellegrino Musto; Vittorio Simeon; Alberto Grossi; Francesca Gay; Sara Bringhen; Alessandra Larocca; Roberto Guariglia; Giuseppe Pietrantuono; Oreste Villani; Giovanni D'Arena; Carmela Cuomo; Clelia Musto; Fortunato Morabito; Maria Teresa Petrucci; Massimo Offidani; Elena Zamagni; Paola Tacchetti; Concetta Conticello; Giuseppe Milone; Antonio Palumbo; Michele Cavo; Mario Boccadoro
Journal:  Stem Cell Res Ther       Date:  2015-04-17       Impact factor: 6.832

5.  Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.

Authors:  Yurie Miyamoto-Nagai; Naoya Mimura; Nobuhiro Tsukada; Nobuyuki Aotsuka; Masaki Ri; Yuna Katsuoka; Toshio Wakayama; Rikio Suzuki; Yoriko Harazaki; Morio Matsumoto; Kyoya Kumagai; Takaaki Miyake; Shuji Ozaki; Katsuhiro Shono; Hiroaki Tanaka; Arika Shimura; Yoshiaki Kuroda; Kazutaka Sunami; Kazuhito Suzuki; Takeshi Yamashita; Kazuyuki Shimizu; Hirokazu Murakami; Masahiro Abe; Chiaki Nakaseko; Emiko Sakaida
Journal:  EJHaem       Date:  2022-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.